Ipamorelin (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously, ideally 30 to 60 minutes before bedtime on an empty stomach to synergize with natural nocturnal GH secretion. For doses at or under 10 units (0.10 mL), consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake vigorously).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL, 1 unit = 0.01 mL » 33 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at 2 to 8 °C for short-term or -20 °C for long-term storage in dry, dark conditions.
• Reconstituted: refrigerate at 2 to 8 °C; use within ~4 weeks with bacteriostatic water.
• For longer storage, freeze aliquots at -20 °C and avoid repeated freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (Ipamorelin, 10 mg each):

• 8 weeks: ~2 vials. 12 weeks: ~2 to 3 vials. 16 weeks: ~3 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (2 vials): 1 bottle. 12 weeks (2 to 3 vials): 1 bottle. 16 weeks (3 vials): 1 bottle.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Ipamorelin has a short half-life (~1.5 to 2.5 hours); consistent daily timing maximizes effects.

How This Works

Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) and stimulates the pituitary gland to release endogenous growth hormone in a pulsatile manner. Unlike earlier growth hormone releasing peptides, ipamorelin is highly selective and does not significantly stimulate ACTH, cortisol, or prolactin release at effective doses. After subcutaneous injection, GH levels peak within approximately 40 minutes and return to baseline by 2 to 3 hours. This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns. Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms, though cycling is recommended as a precautionary measure. Ipamorelin has also demonstrated pro-motility effects in the gastrointestinal tract via GHSR-1a receptors.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports increases in lean body mass and improvements in recovery through GH-mediated anabolic

processes.

• Enhances fat metabolism and supports favorable body composition changes over time.
• High selectivity for GH release with minimal impact on other hormones (ACTH, cortisol, prolactin).
• May support improved gastric motility and digestive function.
• Generally well tolerated with a low incidence of side effects at typical doses.
• Occasional mild injection-site reactions (redness, swelling) may occur; very rare reports of water

retention or increased hunger.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-adequate diet to support muscle synthesis and recovery.
• Combine resistance training and cardiovascular exercise to maximize anabolic and metabolic benefits.
• Prioritize 7 to 9 hours of quality sleep nightly, as GH naturally peaks during deep sleep phases.
• Manage stress levels, as chronic stress and elevated cortisol can blunt GH response.
• Inject on an empty stomach (avoid food 2 to 3 hours before and 30 to 60 minutes after) to optimize GH

release.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue (European Journal of Endocrinology, 1998).
2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharmaceutical Research, 1999).
3. Three-week chronic in vivo ipamorelin treatment: no desensitization of GH release (European Journal of Anatomy, 2002).
4. Ipamorelin for postoperative ileus in bowel resection patients (Int J Colorectal Disease, 2014).